Merck announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.
Source: https://www.marketwatch.com/story/merck ... topstories
Merck could pay up to $3 billion to boost its retinal disease candidate pipeline
